Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the future of gene editing.

Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...

Head and neck cancers often begin in the mouth, throat, or voice box. They're among the most common cancers in the world, affecting over half a million people each year and causing about 300,000 ...

Researchers discovered the secret checkpoints that keep CRISPR precise, revealing how the tool shifts from inactive to active without misfiring. The insight could transform gene therapy, making ...

The U.S. Food and Drug Administration approved the first cell-based gene therapies for sickle cell disease, including the ...

This figure illustrates the evolution of CRISPR technology from 1987 to 2019, presented in a horizontal timeline format and categorized into four generations, each denoted by a distinct color: The ...

You’re reading Book Currents, a weekly column in which notable figures share what they’re reading. Sign up for the Goings On newsletter to receive their selections, and other cultural recommendations, ...

One of the more famous companies in this niche is CRISPR Therapeutics (NASDAQ: CRSP). Is this mid-cap company worth ...

CRISPR technology, enabling precise DNA editing, drives gene-editing stocks with major disease treatment potential. Leading companies like Intellia Therapeutics, CRISPR Therapeutics, and Beam focus on ...